Topic cluster
GLP-1s for Cardiovascular & Comorbidity Outcomes
GLP-1 medications were developed for diabetes and weight loss, but the most consequential clinical evidence of the last three years has been about what these drugs do for the rest of the body — heart attacks, heart failure with preserved ejection fraction, chronic kidney disease, and obstructive sleep apnea. This cluster collects every research article on cardiovascular and comorbidity outcomes, all anchored in published phase 3 trial data.
8 research articles in this cluster · last updated 2026-04-08
SELECT Trial: Semaglutide Cuts Heart Attack Risk 20%
The SELECT trial (Lincoff et al., NEJM 2023) randomized 17,604 non-diabetic adults with established cardiovascular disease to weekly semaglutide 2.4 mg or placebo for nearly four years. The primary cardiovascular endpoint dropped 20% — and the benefit appears largely independent of weight loss. Here's what the trial actually measured and what it should change about how we think about GLP-1 therapy.
STEP-HFpEF: How Semaglutide Treats Heart Failure With Preserved Ejection Fraction
The STEP-HFpEF trial family (Kosiborod et al., NEJM 2023 and 2024) randomized 1,145 patients with heart failure with preserved ejection fraction and obesity to semaglutide 2.4 mg or placebo. The KCCQ symptom score improved 7-8 points more than placebo, body weight dropped 6-11 percentage points more, and the 6-minute walk distance improved 17 meters. Here's the verified trial data and where semaglutide fits alongside the SGLT2 inhibitors in HFpEF care.
FLOW: How Semaglutide Became the First GLP-1 Approved for Diabetic Kidney Disease
The FLOW trial (Perkovic et al., NEJM 2024) randomized 3,533 patients with type 2 diabetes and chronic kidney disease to weekly semaglutide 1.0 mg or placebo and was stopped early for benefit. We walk through the trial design, the 24% reduction in major kidney events, the FDA approval, and how the kidney protection compares to the SGLT2 inhibitor trials.
Tirzepatide for Sleep Apnea: What SURMOUNT-OSA Showed and the FDA's First-Ever OSA Drug Approval
SURMOUNT-OSA (Malhotra et al., NEJM 2024) is the trial that made Zepbound the first medication ever approved by the FDA for obstructive sleep apnea. We walk through the verified trial data: a 25–29 events-per-hour reduction in AHI, both with and without concurrent CPAP, in adults with moderate-to-severe OSA and obesity.
Does a GLP-1 Affect Blood Pressure? Lower, Higher, or Both — The Evidence
A thousand patients a month search 'does semaglutide lower blood pressure' or 'can semaglutide cause high blood pressure.' The honest answer is: GLP-1s lower systolic blood pressure by about 5-7 mmHg on average via weight loss and direct vascular mechanisms, with a small subset of patients experiencing dose-dependent heart-rate increases. Here is the evidence from STEP-1, SURMOUNT-1, SELECT, and the antihypertensive interaction.
GLP-1s and Pregnancy, PCOS, and Fertility: What the FDA Labels and the Trial Evidence Actually Say
Wegovy, Zepbound, Ozempic, and Foundayo are all contraindicated in pregnancy and require discontinuation 2 months before planned conception. We walk through the FDA prescribing information for each drug, the published PCOS pilot trials (Salamun, Jensterle), the contraception interaction during dose escalation, and the emerging 'GLP-1 babies' fertility restoration phenomenon — with primary source citations throughout.
Does a GLP-1 Affect Your Period? Menstrual Cycle Changes, Hormones, and the PCOS Connection
Hundreds of patients a month search 'does tirzepatide affect your period.' GLP-1s do not directly target the menstrual cycle, but the rapid weight loss they produce frequently does — restoring ovulation in PCOS, sometimes triggering temporary irregularity in patients with low body weight, and interacting with oral contraceptive absorption. Here is the evidence and what to do about each scenario.
Jardiance, Farxiga, and SGLT2 Inhibitors vs GLP-1s: Weight, Cardio-Renal Benefits, and Where Each Fits in 2026
SGLT2 inhibitors (Jardiance, Farxiga, Invokana) and GLP-1 receptor agonists (Ozempic, Wegovy, Mounjaro, Zepbound, Foundayo) are the two diabetes drug classes with proven cardiovascular and kidney outcome benefits. We walk through EMPA-REG OUTCOME, EMPEROR-Reduced/Preserved, DECLARE-TIMI 58, DAPA-HF, DAPA-CKD, DELIVER, CANVAS, CREDENCE, and the GLP-1 trials side by side: weight loss magnitudes, MACE/HF/kidney HRs, and where ADA Standards of Care 2025 puts each class.